<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04288583</url>
  </required_header>
  <id_info>
    <org_study_id>2019-5845</org_study_id>
    <nct_id>NCT04288583</nct_id>
  </id_info>
  <brief_title>Bringing Parkinson Care Back Home</brief_title>
  <official_title>Bringing Parkinson Care Back Home</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SUMMARY

      Rationale: For persons with Parkinson's disease (PD), medical decisions are based almost
      exclusively on periodic in-clinic evaluations by a neurologist or a nurse. For a variety of
      reasons, such &quot;snapshots&quot; are unable to capture the actual impact of PD on the patient's
      functioning in their own home environment. Outpatient evaluations cannot detect rare and
      typically domestic events, such as falls. In addition, episodic visits are not well suited to
      detect changes in important lifestyle issues, such as gradual declines in physical activity.

      Objective: To objectively, continuously and accurately collect detailed information on
      (changes in) physical activity and fall patterns among patients with PD in daily life.

      Study design: Observational cohort study in 200 patients with PD, with a 12 month follow-up
      period.

      Study population: Patients with PD (n=200), with an increased fall risk (i.e. at least one
      fall within the last six months).

      Intervention (if applicable): This study does not include an intervention. After a baseline
      assessment on demographics and PD symptoms, patients will use a remote monitoring system at
      home (a pendant falls detector) combined with an smartphone application aimed at falls
      self-reporting, and an application to report medication intake for 12 months. A similar set
      up (i.e.Vital@Home) has been previously tested on feasibility (Dossiernummer: 2017-3382).
      Additionally, patients will report sleep patterns through paper-based diaries.

      Main study parameters/endpoints: The main study parameters are physical activity and number
      of falls. They are remotely registered by the pendant falls detector.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: In this study, no invasive measurements will be performed. The participation is
      free of risks. Subjects could potentially benefit personally from participating in this
      study, as they can use the devices for free during the study and receive periodically
      feedback about physical activity and the occurrence of falls.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">August 8, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 8, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Falls</measure>
    <time_frame>Continuously over 12 months</time_frame>
    <description>Number of alls measured with wearable sensors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical activity</measure>
    <time_frame>Continuously over 12 months</time_frame>
    <description>Minutes of physical activity performed during daily-life measured with wearable sensors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>Twice - baseline and after 12 months</time_frame>
    <description>LASA physical activity questionnaire, in which the higher the score the better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking capacity</measure>
    <time_frame>Once - baseline</time_frame>
    <description>6-meter walking test, in which the higher the distance walked the better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Falls</measure>
    <time_frame>Twice - baseline and after 12 months</time_frame>
    <description>Falls history questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional lower extremity strength</measure>
    <time_frame>Once - baseline</time_frame>
    <description>Five-times-sit-to-stand, in which the faster the task is completed the better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of falling</measure>
    <time_frame>Twice - baseline and after 12 months</time_frame>
    <description>Falls Efficacy Scale International, with scores ranging from 16 to 64 points, in which the a higher score indicates worse fear of falling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>Continuously over 12 months</time_frame>
    <description>Number of days in which participants worn the device for more than 8 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients demographics</measure>
    <time_frame>Once - baseline</time_frame>
    <description>Demographics questionnaire (age, gender, education, disease duration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease severity</measure>
    <time_frame>Part III - once at baseline. Part I, II and IV - twice baseline and after 12 months</time_frame>
    <description>Movement Disorders Society - Unified Parkinson's Disease Rating Scale part I-IV, with scores ranging from 0 to 272, in which the higher the score the worse symptoms are.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease status</measure>
    <time_frame>Once - baseline</time_frame>
    <description>Hoehn &amp; Yahr stadia, ranging from 0-5, in which the higher the worse the disease status is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication</measure>
    <time_frame>Continuously over 12 months</time_frame>
    <description>Medication intake diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Balance - I</measure>
    <time_frame>Once - baseline</time_frame>
    <description>Mini-BESTest, ranging from 0 to 28, in which the higher the score the better the balance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Balance - II</measure>
    <time_frame>Once - baseline</time_frame>
    <description>Single leg stance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freezing of gait - I</measure>
    <time_frame>Twice - baseline and after 12 months</time_frame>
    <description>New freezing of gait questionnaire, ranging from 0 to 24, in which the higher the score the worse is the freezing of gait.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freezing of gait - II</measure>
    <time_frame>Once - baseline</time_frame>
    <description>Rapid turns test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition</measure>
    <time_frame>Once - baseline</time_frame>
    <description>Montreal Cognitive Assessment, with scores ranging from 0 to 30, in which the higher the better the cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Twice - baseline and after 12 months</time_frame>
    <description>Pittsburgh Sleep Quality Index, with scores ranging from 0 to 21, in which the higher the worse the sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality and quantity</measure>
    <time_frame>Once for a full week</time_frame>
    <description>Sleep diary</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Parkinson Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        200 patients diagnosed with Parkinson's disease with an increased fall risk (i.e. who
        reported at least one fall in the last 6 months).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must confirm that they have been diagnosed with Parkinson's Disease by a
             neurologist (self-reported)

          -  Age 18 or older

          -  At least 1 fall incident in the previous 6 months. A fall is defined as any unexpected
             event that caused the person to unintentionally land on any lower surface (object,
             floor, or ground), regardless of any sustained injury (self-reported)

          -  Able and willing to provide written informed consent in accordance with Good Clinical
             Practice, and national and local regulation

          -  Fluent in Dutch

        Exclusion Criteria:

          -  The patients receives advanced therapy for their Parkinson's disease (deep brain
             stimulation, duodopa pump, apomorphine pump);

          -  The patients shows cognitive of psychiatric impairments that may hinder successful
             completion of the study protocol (as judged by the researcher running the
             recruitment).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nienke M de Vries, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana LÃ­gia Silva de Lima, Dr</last_name>
    <phone>024 - 361 5285</phone>
    <email>ana.silvadelima@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nienke M de Vries, Dr</last_name>
    <phone>024 - 361 5285</phone>
  </overall_contact_backup>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wearable sensors</keyword>
  <keyword>Falls</keyword>
  <keyword>Physical activity</keyword>
  <keyword>Parkinson's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data will be anonymized. The wearable sensor data will not be available for re-use and/or sharing.</ipd_description>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After study completion.</ipd_time_frame>
    <ipd_access_criteria>Access to the data will be granted for those performing research about Parkinson's disease.</ipd_access_criteria>
    <ipd_url>https://easy.dans.knaw.nl/ui/home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

